Edward Miracco, Ph.D.

Director, RNA Chemical Biology/External Technology Investments at Moderna, Inc.

Speaker

When I first learned about pseudouridine in the early 2000’s, I was intrigued by its ubiquity yet lack of functional understanding. This led me to pursue a graduate degree in the mechanistic enzymology of RNA editing, and more specifically of the pseudouridine synthases. I continued my connection to pseudouridine with a cryoEM post-doc on telomerase, and during this time, key papers were published on mRNA containing pseudouridine leading to dramatic increases to protein production and decreases in immune activation. I was hooked. I joined Moderna in the mRNA process development group as soon as I could and haven’t looked back. I have held roles in LNP process development, Quality, and now RNA chemical biology and External Technology Investments.